[Asia Economy Reporter Lee Gwan-joo] Huons recently announced on the 27th that through its US subsidiary Huons USA, it has signed a supply contract for local anesthetics with the US pharmaceutical distribution company McKesson.
The contracted product is '1% Lidocaine Hydrochloride Injection 5ml vial,' for which it obtained FDA ANDA (Abbreviated New Drug Application) approval in May 2020. The initial shipment of the first batch is scheduled for August.
Huons plans to promote the high quality of Korean injectable drugs through McKesson's extensive distribution network and contribute to resolving the ongoing shortage of essential medicines in the US. Lidocaine injection has been an essential medicine experiencing chronic supply shortages in the US since the 2010s.
A Huons official stated, "We expect Huons' position in the North American essential injectable drug market to be further strengthened starting with this contract," and added, "We will expedite the FDA approval process for additional products under discussion and take the lead in showcasing the strength of domestically produced injectable drugs to the global market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
